The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience

Girish Badarkhe; Radheshyam Naik

doi:10.4103/ijmpo.ijmpo_154_19

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 530-534
DOI: 10.4103/ijmpo.ijmpo_154_19

Original Article

The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience

Authors

Girish Badarkhe

¹HCG Manavata Cancer Centre, Nashik, Maharashtra, India
Radheshyam Naik

²HCG Cancer Centre, Bengaluru, Karnataka, India

Abstract

Introduction

Plerixafor is a CXCR4 antagonist which is administered along with granulocyte-colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), who failed the mobilization with G-CSF alone.

Methodology

This was a single-center, retrospective study of the efficacy of the plerixafor and G-CSF in 32 patients with NHL (n = 11), MM (n = 11), and Hodgkin lymphoma (HL) (n = 10) who failed mobilization with G-CSF alone.

Results

A median number of 1.21 × 10⁶, 1.32 × 10⁶, and 6.73 × 10⁶ CD34 + cells were mobilized in patients with MM, NHL, and HL, respectively. Overall, 31 (96.8%) patients mobilized more than 2 × 10⁶ CD34 + stem cells and 21 (33.75%) patients mobilized more than 5 × 10⁶ CD34 + stem cells. All 32 (100%) patients underwent hematopoietic stem cell transplantation. There were no adverse drug events reported.

Conclusion

This retrospective study shows that plerixafor is an effective and safe mobilization agent in patients with NHL, MM, and HL who have failed mobilization with G-CSF alone.

Keywords

Hematopoietic stem cell transplantation - multiple myeloma - Non-Hodgkin lymphoma - plerixafor

Full Text

References

References
1 Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: Future directions. Bone Marrow Transplant 2009; 43: 181-95
2 Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114: 198-205
3 Josefsen D, Rechnitzer C, Parto K, Kvalheim G. The use of plerixafor for peripheral blood stem cell mobilisation reduces the frequency of mobilisation failure in patients planned to undergo autologous transplantation. Eur Haematol 2010; 4: 24-9
4 Sehn LH, Fenske TS, Laport GG. Follicular lymphoma: Prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: S82-91
5 Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83
6 Wach M, Cioch M, Hus M, Jawniak D, Legiec W, Malek M. et al. Treatment of multiple myeloma patients with autologous stem cell transplantation – A fresh analysis. Folia Histochem Cytobiol 2011; 49: 248-54
7 Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Curr Oncol 2016; 23: e409-30
8 Jillella AP, Ustun C. What is the optimum number of CD34+peripheral blood stem cells for an autologous transplant?. Stem Cells Dev 2004; 13: 598-606
9 Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW. et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506-12
10 Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L. et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9
11 Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92
12 Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I. et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125: 605-12
13 Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J. et al. Patients mobilizing large numbers of CD34+cells (”super mobilizers”) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437-41
14 Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003
15 Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ. et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: Results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1564-72
16 Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J. et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+cells. Biol Blood Marrow Transplant 2013; 19: 670-5
17 Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: An emerging concept. Transfusion 2012; 52: 906-14
18 Lysák D, Kořístek Z, Gašová Z, Skoumalová I, Jindra P. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?. J Clin Apher 2011; 26: 9-16
19 Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-42
20 Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on untreated multiple myeloma patients. Leukemia mobilization of peripheral blood stem cells in previously 2008; 22: 1280-1
21 Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J. et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011; 86: 488-95
22 Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295-308
23 Canales MA, Fernández-Jiménez MC, Martín A, Arrieta R, Caballero MD, Díez J. et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494-8
24 Duarte FB, Fernandes MG, Kaufmann J, Barroso KS, Leitão JP, Araujo BS. et al. Hodgkin's lymphoma evaluation of patients submitted to autologous transplantation of hematopoietic cells in the hematology service of the hospital Walter Cantídio – Fortaleza, Brazil. Rev Assoc Med Bras (1992) 2016; 62 Suppl 1: 34-8
25 D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S. et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-63
26 Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Shimoni A. et al. Plerixafor (Mozobil): A stem cell-mobilizing agent for transplantation in lymphoma patients predicted to be poor mobilizers – A pilot study. Acta Haematol 2016; 135: 29-36
27 Gazitt Y, Freytes CO, Akay C, Badel K, Calandra G. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007; 16: 657-66
28 Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C. et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-8
29 Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion 2012; 52: 1785-91
30 Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-8
31 Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J. et al. Acombination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: Results of a European phase II study. Cytotherapy 2009; 11: 992-1001
32 Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S. et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107: 3772-8
33 Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ. et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: Results of the prospective PREDICT trial. Haematologica 2013; 98: 172-8
34 DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E. et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73
35 DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL. et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6